Fullcircle Wealth LLC Raises Position in Sanofi (NASDAQ:SNY)

Fullcircle Wealth LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 9.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,144 shares of the company’s stock after acquiring an additional 424 shares during the quarter. Fullcircle Wealth LLC’s holdings in Sanofi were worth $248,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in SNY. Crestline Management LP purchased a new position in shares of Sanofi in the fourth quarter worth $343,000. Cetera Investment Advisers increased its holdings in Sanofi by 5.2% in the 4th quarter. Cetera Investment Advisers now owns 199,138 shares of the company’s stock worth $9,604,000 after buying an additional 9,818 shares in the last quarter. Brown Advisory Inc. raised its position in Sanofi by 82.1% in the 4th quarter. Brown Advisory Inc. now owns 240,053 shares of the company’s stock worth $11,578,000 after buying an additional 108,239 shares during the last quarter. Bayesian Capital Management LP bought a new position in Sanofi during the 4th quarter valued at about $1,875,000. Finally, Bank of America Corp DE boosted its holdings in shares of Sanofi by 3.8% during the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company’s stock valued at $579,587,000 after acquiring an additional 441,637 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. The Goldman Sachs Group began coverage on Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price on the stock. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $63.33.

Sanofi Stock Performance

NASDAQ:SNY opened at $52.13 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a 50-day simple moving average of $54.37 and a two-hundred day simple moving average of $52.03. The firm has a market capitalization of $131.69 billion, a PE ratio of 20.94, a P/E/G ratio of 1.01 and a beta of 0.55. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the company posted $1.78 EPS. The firm’s revenue was down 11.0% on a year-over-year basis. Analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be issued a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. This is an increase from Sanofi’s previous annual dividend of $1.48. Sanofi’s dividend payout ratio is currently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.